Straub CE marks endovascular catheters for further indications
This article was originally published in Clinica
Straub Medical has CE marked its new-generation Rotarex S and Aspirex S families of rotational endovascular catheters for additional indications and subsequently upgraded the classification of the devices from Class II to III. The catheters, in combination with the Straub Medical Drive System, can now be marketed for the percutaneous transluminal removal of material from occlusions of all blood vessels outside the cardiopulmonary, coronary and cerebral circulations. Both catheters may be used in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses. Aspirex S catheters are intended to be used for the removal of fresh thrombotic or thromboembolic material, and Rotarex S catheters are designed to remove thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions. The Wangs, Switzerland company initially CE marked the devices in 1999.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.